Global Longlife Hospital and Research Limited appointed M/s. J J Patel & Associates, Chartered Accountants, as its Internal Auditor for the financial year 2026-2027. The Board of Directors approved the appointment during a meeting held on May 30, 2026. The firm will provide services in audit and assurance, GST matters, income tax, and financial consultancy.

The meeting commenced at 01:30 P.M. and concluded at 02:30 P.M. on May 30, 2026. The appointment was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

Global Longlife Hospital & Research Limited convened a Board of Directors meeting on May 07, 2026, at its registered office in Ahmedabad, wherein the Board approved the audited financial results for the half year and year ended March 31, 2026. The statutory audit was conducted by M/s R B Gohil & Co., Chartered Accountants (Firm Registration Number: 119360W), who issued an unmodified opinion on the financial results. The meeting commenced at 02:00 P.M. and concluded at 03:45 P.M.

Financial Performance: Sharp Decline in Revenue and Profitability

The company's financial results for FY26 reflect a significant deterioration compared to the previous year. Total income for the year ended March 31, 2026, stood at ₹0.52 lakhs, a steep decline from ₹559.34 lakhs recorded in the year ended March 31, 2025. Revenue from operations was nil for FY26, compared to ₹57.73 lakhs in FY25. The company reported a net loss of ₹171.95 lakhs for FY26, reversing a net profit of ₹19.87 lakhs in FY25. Total expenses for FY26 were ₹99.32 lakhs against ₹549.42 lakhs in FY25.

The following table summarises the key financial metrics for the year ended March 31, 2026, compared to the prior year:

Half Year Performance

For the half year ended March 31, 2026, the company reported nil total income and a net loss of ₹39.61 lakhs. In the preceding half year ended September 30, 2025 (unaudited), total income was ₹0.52 lakhs and the net loss was ₹132.34 lakhs. For the comparative half year ended March 31, 2025, total income was ₹(67.36) lakhs and the net loss was ₹103.99 lakhs.

Balance Sheet and Cash Position

As at March 31, 2026, the company's total assets stood at ₹2,376.13 lakhs, down from ₹2,684.46 lakhs as at March 31, 2025. Total shareholders' funds declined to ₹2,374.93 lakhs from ₹2,678.88 lakhs, reflecting the net loss for the year. Reserves and surplus decreased to ₹1,324.93 lakhs from ₹1,628.88 lakhs. The paid-up equity share capital remained unchanged at ₹1,050.00 lakhs with a face value of ₹10.00 per share.

The company's cash and cash equivalents declined to ₹1,701.70 lakhs as at March 31, 2026, from ₹2,149.18 lakhs as at March 31, 2025. Net cash used in operating activities for FY26 was ₹(450.97) lakhs, compared to net cash generated of ₹1,232.07 lakhs in FY25. Net cash from investment activities was ₹3.52 lakhs in FY26 versus ₹2,179.88 lakhs in FY25. Net cash used in financing activities was ₹(0.03) lakhs in FY26 compared to ₹(1,301.30) lakhs in FY25.

Board Approves Name Change and Object Clause Amendment

In addition to the financial results, the Board of Directors approved two significant corporate actions, both subject to shareholder and regulatory approvals:

• Name Change: Alteration of the name clause of the Memorandum of Association from Global Longlife Hospital and Research Limited to one of the following — Kanzi Enterprise Limited, Asahi Enterprise Limited, or Siddhaa Enterprise Limited — subject to approval of shareholders and the Ministry of Corporate Affairs.
• Object Clause Amendment: Alteration of Clause III (A), the Main Object Clause of the Memorandum of Association. The existing Clause III (A), which represents the healthcare industry, will be deleted and a new Clause III (A) representing the trade and service industry will be added, subject to approval of members.

Notes and Disclosures

The company operates in a single segment — Medical and Healthcare Services — and accordingly no additional segment reporting disclosures are required under AS-17. The financial results have been prepared in accordance with accounting standards notified under Section 133 of the Companies Act, 2013, and the company is exempt from the applicability of Ind-AS as it is listed on the SME Platform of BSE. The results have been reviewed and recommended by the Audit Committee and approved by the Board at its meeting held on May 07, 2026. Previous period figures have been re-grouped or re-classified wherever necessary to conform to the current period's classification.